


# Therapeutic Fc-Fusion Proteins

Edited by Steven M. Chamow,  
Thomas Ryll, Henry B. Lowman, and Deborah Farson



WILEY Blackwell



*Edited by*  
*Steven M. Chamow,*  
*Thomas Ryll,*  
*Henry B. Lowman,*  
*and Deborah Farson*

**Therapeutic Fc-Fusion  
Proteins**

## ***Related Titles***

Dübel, S., Reichert, J.M. (eds.)

### **Handbook of Therapeutic Antibodies**

2 Edition

2014

Print ISBN: 978-3-527-32937-3, also available in digital formats

Knäblein, J. (ed.)

### **Modern Biopharmaceuticals Recent Success Stories**

2013

Print ISBN: 978-3-527-32283-1, also available in digital formats

Bertolini, J., Goss, N., Curling, J. (eds.)

### **Production of Plasma Proteins for Therapeutic Use**

2013

Print ISBN: 978-0-470-92431-0, also available in digital formats

Kontermann, R. (ed.)

### **Therapeutic Proteins Strategies to Modulate Their Plasma Half-lives**

2012

Print ISBN: 978-3-527-32849-9, also available in digital formats

Reilly, R.M. (ed.)

### **Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer**

2010

Print ISBN: 978-0-470-24372-5, also available in digital formats

Gottschalk, U. (ed.)

### **Process Scale Purification of Antibodies**

2009

Print ISBN: 978-0-470-20962-2, also available in digital formats

Schmidt, S.R. (ed.)

### **Fusion Protein Technologies for Biopharmaceuticals**

2013

Print ISBN: 978-0-470-64627-4, also available in digital formats



*Edited by*  
*Steven M. Chamow, Thomas Ryll, Henry B. Lowman,*  
*and Deborah Farson*

## **Therapeutic Fc-Fusion Proteins**

**WILEY** Blackwell

## Editors

**Dr. Steven M. Chamow**  
Chamow & Associates, Inc.  
San Mateo, CA 94403  
USA

**Dr. Thomas Ryll**  
Biogen Idec  
Cambridge, MA 02142  
USA

**Dr. Henry B. Lowman**  
CytomX Therapeutics, Inc.  
South San Francisco, CA 94080  
USA

**Deborah Farson**  
FarsonInk  
Santa Fe, NM 87505  
USA

**Cover Drawings:** Laura Shih

Top row: Tumor necrosis factor receptor-immunoglobulin G1 (TNFR-Fc) fusion protein; middle row: Interleukin receptor 1-immunoglobulin G1 (L1R-Fc) fusion protein; bottom row: Vascular endothelial growth factor receptor-immunoglobulin G1 (VEGFTrap) Fc fusion protein.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

**Library of Congress Card No.:** applied for

### British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

### Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Print ISBN:** 978-3-527-33317-2

**ePDF ISBN:** 978-3-527-67529-6

**ePub ISBN:** 978-3-527-67528-9

**Mobi ISBN:** 978-3-527-67530-2

**oBook ISBN:** 978-3-527-67527-2

**Cover Design** Adam-Design, Weinheim, Germany

**Typesetting** Thomson Digital, Noida, India

**Printing and Binding** Markono Print Media Pte Ltd, Singapore

Printed on acid-free paper.

## Contents

**Preface** XIII

**List of Contributors** XV

<b>1</b>	<b>Introduction: Antibody Structure and Function</b>	<b>1</b>
	<i>Arvind Rajpal, Pavel Strop, Yik Andy Yeung, and Javier Chaparro-Riggers, and Jaume Pons</i>	
1.1	Introduction to Antibodies	1
1.2	General Domain and Structure of IgG	6
1.2.1	Structural Aspects Important for Fc Fusion(s)	6
1.2.1.1	Fc Protein–Protein Interactions	6
1.2.1.2	Fc Glycosylation	8
1.2.1.3	Hinge and Interchain Disulfide Bonds	8
1.3	The Neonatal Fc Receptor	9
1.3.1	FcRn Function and Expression	9
1.3.2	Species Difference in FcRn	13
1.3.3	Engineering to Modulate Pharmacokinetics	14
1.3.3.1	Fc Engineering	14
1.3.3.2	Other Engineering Efforts to Modify PK of an IgG or Fc Fusion	15
1.4	Introduction to FcγR- and Complement-Mediated Effector Functions	16
1.4.1	Cell Lysis and Phagocytosis Mediation	17
1.4.2	FcγR-Mediated Effector Functions	17
1.4.2.1	FcγR Biology	17
1.4.2.2	Expression Profiles	18
1.4.2.3	Therapeutic Relevancy	19
1.4.3	Complement	20
1.4.3.1	C1q Biology	20
1.4.3.2	Therapeutic Relevancy	20
1.4.4	Modifying Effector Functions	21
1.4.4.1	FcγR-Dependent Effector Function	21
1.4.4.2	Engineering	22
1.4.4.3	Glycoengineering	22

- 1.4.4.4 Reducing and Silencing Effector Function 23
- 1.5 Current Trends in Antibody Engineering 25
  - 1.5.1 Bispecific 25
  - 1.5.2 Drug Conjugates 26
- References 28

## Part One Methods of Production for Fc-Fusion Proteins 45

### 2 Fc-Fusion Protein Expression Technology 47

*Jody D. Berry, Catherine Yang, Janean Fisher, Ella Mendoza, Shanique Young, and Dwayne Stupack*

- 2.1 Introduction 47
- 2.2 Expression Systems Used for Fc-Fusion Proteins 50
  - 2.2.1 Expression Using Mammalian Cell Lines 50
    - 2.2.1.1 Host Cells 51
    - 2.2.1.2 Codon Optimization 52
    - 2.2.1.3 Vectors 52
    - 2.2.1.4 Stable versus Transient Expression 53
    - 2.2.1.5 Viral Transduction and Transfection Methods 55
  - 2.2.2 Expression Using Prokaryotic Cells 57
    - 2.2.2.1 Vectors 59
    - 2.2.3 Expression Using Baculovirus/Insect Cells 60
      - 2.2.3.1 Host Cells 61
      - 2.2.3.2 Vectors 61
      - 2.2.3.3 Additional Considerations 62
- 2.3 Summary 62
- References 62

### 3 Cell Culture-Based Production 67

*Yao-Ming Huang, Rashmi Kshirsagar, and Barbara Woppmann, and Thomas Ryll*

- 3.1 Introduction 67
- 3.2 Basic Aspects of Industrial Cell Culture 69
  - 3.2.1 The Central Role of the Production Cell Line 69
  - 3.2.2 Production Systems 70
  - 3.2.3 Production Mode: Fed-Batch or Perfusion? 71
  - 3.2.4 Scale-Up 73
  - 3.2.5 Raw Materials and Process Control 74
  - 3.2.6 How to Develop or Optimize a Culture Production Process for Fc-Fusion Molecules 74
- 3.3 Specific Process Considerations for Fc-Fusion Molecules 77
  - 3.3.1 Product Quality Challenges 77
  - 3.3.2 Process Strategies and Process Parameters 78
    - 3.3.2.1 Temperature and Misfolding 78

3.3.2.2	Other Process Parameters	79
3.3.2.3	Glycosylation	81
3.4	Case Studies	82
3.4.1	LTBr-Fc (Baminercept)	82
3.4.2	rFVIII Fc	85
3.5	Conclusions	87
	References	87
<b>4</b>	<b>Downstream Processing of Fc-Fusion Proteins</b>	<b>97</b>
	<i>Abhinav A. Shukla and Uwe Gottschalk</i>	
4.1	Introduction and Overview of Fc-Fusion Proteins	97
4.2	Biochemistry of Fc-Fusion Proteins	99
4.3	Purification of Fc-Fusion Proteins from Mammalian Cells	100
4.3.1	Platform Approaches for Downstream Purification	100
4.3.2	Comparison of Protein A Chromatography, Viral Inactivation, and Polishing Steps	103
4.4	Purification of Fc-Fusion Protein from Microbial Systems	107
4.5	Future Innovations in Fc-Fusion Protein Downstream Processing	109
4.6	Conclusions	110
	References	111
<b>5</b>	<b>Formulation, Drug Product, and Delivery: Considerations for Fc-Fusion Proteins</b>	<b>115</b>
	<i>Wenjin Cao, Deirdre Murphy Piedmonte, and Margaret Speed Ricci, and Ping Y. Yeh</i>	
5.1	Challenges of Molecule Design and Protein Formulation	115
5.2	The Promise of Fc-Fusion Proteins	116
5.3	Current Landscape of Commercial Antibody-Related Products	118
5.4	Fc Conjugates Compared to mAb Counterparts	118
5.5	Factors in Selecting Liquid versus Lyophilized Formulations	126
5.6	Advantages and Disadvantages of a Lyophilized Product	126
5.7	The General Lyophilization Formulation Strategy for Fc-Fusion Proteins	127
5.7.1	pH and Buffer	128
5.7.2	Stabilizing Agents (Cryoprotectant and Lyoprotectant)	129
5.8	Bulking Agent	132
5.9	Surfactant	134
5.10	The Impact of Residual Moisture	135
5.11	Practical Considerations for Low-Protein-Concentration Lyophilized Products	138
5.12	Drug Delivery Considerations	139
5.13	Device Considerations	141
5.14	Assessing Feasibility of a Multidose Formulation	142

5.15	Overage Considerations	142
5.16	Summary	143
	References	144
<b>6</b>	<b>Quality by Design Applied to a Fc-Fusion Protein: A Case Study</b>	<b>155</b>
	<i>Alex Eon-Duval, Ralf Gleixner, Pascal Valax, Miroslav Soos, Benjamin Neunstoecklin, Massimo Morbidelli, and Hervé Broly</i>	
6.1	Introduction	155
6.1.1	Atacept: A Novel Immunomodulator with B Cell Targeting Properties	155
6.1.2	Molecular Characteristics	155
6.1.3	Quality by Design Concept	157
6.2	Critical Quality Attributes	159
6.3	Critical Process Parameters	160
6.4	Process Characterization	161
6.5	Global Multistep Design Space	164
6.6	Robustness Studies	168
6.7	Adaptive Strategy	169
6.8	Engineering Design Space	171
6.8.1	Principle of the Engineering Design Space	171
6.8.2	The Shear Stress as One Element of the Engineering Design Space	173
6.9	Control Strategy	176
6.9.1	Process Controls	177
6.9.2	Testing Controls	177
6.9.3	Process Monitoring	179
6.9.4	Material Control	179
6.10	Continuous Process Verification	180
6.11	Expanded Change Protocol and Continual Improvement	182
6.12	Business Case	183
	References	187
<b>7</b>	<b>Analytical Methods Used to Characterize Fc-Fusion Proteins</b>	<b>191</b>
	<i>Esohe Idusogie and Michael Mulkerrin</i>	
7.1	Background	191
7.2	Product Characterization	193
7.2.1	Physiochemical Analysis	195
7.2.1.1	Measurement of Strength by Absorbance at 280 nm	195
7.2.1.2	Determination of Identity and Evaluation of Charge Variants	195
7.2.1.3	Measurement of Purity and Integrity	198
7.2.1.4	Mass Analysis and Confirmation of Primary Structure	198
7.2.1.5	Oligosaccharide Analysis	199
7.2.1.6	Purity (Product-Related Variants)	200
7.2.2	Measurement of Potency	201
7.2.3	Process-Related Impurities and Contaminants	204

7.2.3.1	Host Cell Protein	204
7.2.3.2	Residual DNA	205
7.2.3.3	Residual Protein A	206
7.2.3.4	Tests for Contaminants	206
7.3	Characterization of the Reference Standard	207
7.4	Typical Product Release and Stability Assays	207
7.5	Analytical Method Qualification and Validation	210
	References	212

## Part Two Case Studies of Therapeutic Fc-Fusion Proteins 217

### 8 Introduction to Therapeutic Fc-Fusion Proteins 219

*Jody D. Berry*

8.1	Therapeutic Fc-Fusion Proteins	219
8.2	Background	221
8.3	Fc-Fusion Constructs Have Increased In Vivo Stability	222
8.4	Immunoglobulin-Mediated Effector Function	223
8.5	Considerations in Fc-Fusion Protein Design	226
8.6	Fc-Fusion Proteins Approved for Use in the United States	226
8.6.1	Alefacept	226
8.6.2	Etanercept	227
8.6.3	Abatacept and Belatacept	227
8.6.4	Aflibercept	228
8.6.5	rFVIIIIFc and rFIXFc	228
8.6.6	Rilonacept	229
8.6.7	Romiplostim	229
8.6.8	Trebananib	229
8.7	Concluding Remarks	229
	References	230

### 9 Alefacept 233

*Deborah A. Farson*

9.1	Introduction	233
9.2	Chronic Plaque Psoriasis	233
9.3	Conventional Treatments for Psoriasis	234
9.4	Preclinical Development	234
9.4.1	CD2/LFA-3	234
9.4.2	Fusion Protein Alefacept (LFA3TIP)	236
9.5	Preclinical Primate Studies	237
9.6	Phase 1 and 2 Human Clinical Studies	240
9.7	Phase 3 Studies	240
9.7.1	Study Design	242
9.7.1.1	Eligibility	242
9.7.1.2	Dosing and Blood Work	244

9.7.1.3	Endpoints	244
9.7.1.4	Statistical Analysis	244
9.7.1.5	Intravenous Studies 711 and 724	244
9.7.1.6	Intramuscular Studies 712 and 717	245
9.7.2	Efficacy	245
9.7.2.1	Patient Population	245
9.7.2.2	CD4 Monitoring	246
9.7.2.3	PASI and PGA Results	246
9.7.2.4	Quality of Life	247
9.7.2.5	Remittance	247
9.7.3	Multiple Courses of Treatment	247
9.8	Clinical Pharmacology	248
9.9	Clinical Safety	249
9.9.1	Adverse Events	249
9.9.2	Infection	250
9.9.3	Cancer	250
9.9.4	Laboratory Tests	250
9.10	Amevive Discontinued	250
	References	251

## 10 Etanercept 255

*Johanna Grossman and Steven M. Chamow*

10.1	Introduction	255
10.1.1	TNF Structure and Function	255
10.1.2	TNF Receptor Types	256
10.1.3	TNF Receptor Signaling	256
10.1.4	Role of TNF in Chronic Inflammatory Disease	259
10.1.5	Rheumatoid Arthritis	259
10.1.6	Juvenile Idiopathic Arthritis	260
10.1.7	Psoriatic Arthritis	260
10.1.8	Ankylosing Spondylitis	260
10.1.9	Crohn's Disease	261
10.1.10	Ulcerative Colitis	261
10.1.11	Psoriasis	261
10.2	Design, Construction, and Characterization of TNFR-Fc-Fusion Protein	262
10.2.1	State of Therapeutic Antibodies and Rationale for a Receptor-Fc-Fusion Protein	262
10.3	Etanercept Preclinical Development	264
10.3.1	Binding and TNF Inhibitory Activity	265
10.3.2	Inhibition of TNF Activity	265
10.3.3	Preclinical Efficacy	266
10.3.4	Pharmacokinetics and Pharmacodynamics	266
10.3.5	Toxicology	267
10.4	Etanercept Key Clinical Trials	267



10.4.1	Rheumatoid Arthritis	267
10.4.2	Polyarticular Juvenile Idiopathic Arthritis	269
10.4.3	Psoriatic Arthritis	270
10.4.4	Ankylosing Spondylitis	270
10.4.5	Plaque Psoriasis	271
10.4.6	Other Potential Indications	272
10.5	Competitive Landscape	273
10.6	Conclusions	273
	References	274
<b>11</b>	<b>Abatacept and Belatacept</b>	<b>283</b>
	<i>Robert J. Peach</i>	
11.1	Introduction	283
11.2	Design, Construction, and Characterization of Abatacept	285
11.3	Immunosuppressive Properties of Abatacept	288
11.4	Rational Design and Characterization of Belatacept	291
11.5	Belatacept Activity in Primate Renal Transplant Studies	294
11.6	Abatacept Clinical Development	295
11.7	Belatacept Clinical Development	299
11.8	Concluding Remarks	302
	References	303
<b>12</b>	<b>Aflibercept</b>	<b>311</b>
	<i>Angela L. Linderholm and Steven M. Chamow</i>	
12.1	Introduction	311
12.2	Clinical Indications	311
12.2.1	Age-Related Macular Degeneration	311
12.2.2	Macular Edema with CRVO	315
12.2.3	Metastatic Colorectal Cancer	316
12.3	Characterization of Aflibercept	317
12.4	Preclinical Studies with Aflibercept	320
12.5	Clinical Studies with Aflibercept	325
12.5.1	Aflibercept and AMD	325
12.5.2	Aflibercept and Cancer	327
12.5.2.1	Single-Agent Phase 1 Studies	327
12.5.2.2	Combination Phase 1 Studies	332
12.5.2.3	Single-Agent Phase 2 Studies	332
12.5.2.4	Combination Phase 2 and 3 Studies	335
12.6	Summary	336
	References	336
<b>13</b>	<b>Recombinant Factor VIII– and Factor IX–Fc Fusions</b>	<b>351</b>
	<i>Robert T. Peters and Judy R. Berlfein</i>	
13.1	Introduction	351
13.1.1	Treatment for Hemophilia	351

13.2	Structure and Function of Factor IX and Factor VIII	352
13.2.1	Factor IX	352
13.2.2	Factor VIII	354
13.3	Rationale and Design of rFIXFc- and rFVIII-Fc-Fusion Proteins	356
13.3.1	Fc/FcRn Pathway for Half-Life Extension and the Monomeric Fc-Fusion	356
13.3.2	Beyond Science: Outside Factors for Applying Monomeric Fc Technology to Hemophilia	356
13.3.3	rFIXFc: Putting It Into Practice	358
13.3.4	rFVIII-Fc: Putting It Into Practice	363
13.4	Development of a Clinical Candidate and Beyond	365
13.4.1	Preclinical and Clinical Development	365
13.4.1.1	Preclinical Development	366
13.4.1.2	Clinical Development	367
	References	368

<b>Index</b>	<b>371</b>
--------------	------------

## Preface

Fc-fusion proteins – engineered polypeptides that combine biologically active peptides or protein domains with the crystallizable fragment (Fc) domain of an antibody – have become widely used agents both in research and in clinical practice. The fact that these molecules resemble antibodies in so many aspects of structure, function, expression, purification, and pharmacology has enabled them to be rapidly integrated into a variety of assays, preclinical studies, and clinical applications through leveraging the prior experience with monoclonal antibodies. In the years following the 1989 report from Genentech by Dan Capon and colleagues on an Fc-fusion protein or “immunoadhesin” composed of CD4 linked to an antibody Fc, a variety of different receptor extracellular domains were produced in this format. An earlier volume, *Antibody Fusion Proteins*, by Chamow and Ashkenazi (Wiley, 1999) highlighted progress up to the stage of the first therapeutic Fc fusions progressing through clinical trials. Etanercept became the first FDA-approved therapeutic fusion protein in 1998 and has since become one of the most clinically and commercially successful therapeutics. However, the story of therapeutic Fc fusions does not end here. On the contrary, a growing number of these molecules are being developed as biotherapeutics, including Fc-fusion proteins composed of heterodimeric polypeptide chains and others containing novel peptide mimotopes attached to Fc fragments. We therefore thought it important to review the literature and experience in developing this novel class of biologics – hence the current volume, *Therapeutic Fc-Fusion Proteins*, which brings up-to-date information on the processes of designing and producing these molecules and highlights some of the most prominent case studies from clinical experience.

Owing to the crucial components of antibody structure and function in the design, production, and use of therapeutic Fc fusions, we begin the book with an extensive introduction to the structure and function of IgG molecules (Chapter 1). This is followed by Part One, a series of chapters summarizing state-of-the-art approaches for producing therapeutic Fc proteins: Chapter 2 presents the principles of design and expression systems; Chapter 3, cell culture production; Chapter 4, downstream processing; Chapter 5, formulation and delivery; Chapter 6, quality by design; and Chapter 7, analytical characterization. These chapters provide a roadmap for the development and life cycle of manufacturing processes for therapeutic Fc fusions. Part Two begins with a synopsis (Chapter 8) of clinically significant Fc-fusion

proteins that have been approved or are in late-stage clinical trials. Subsequent chapters present case studies of a subset of these, selected for their unique features in terms of molecular design and/or mechanism of action: alefacept, a lymphocyte function-associated antigen 3 (LFA-3) fusion (Chapter 9); etanercept, a tumor necrosis factor (TNF) receptor fusion (Chapter 10); abatacept and belatacept, cytotoxic T-lymphocyte antigen 4 (CTLA-4) fusions (Chapter 11); aflibercept, a vascular endothelial growth factor (VEGF) receptor fusion (Chapter 12); and factor VIII/IX fusions (Chapter 13). In several cases, we have included authors who were involved directly in development of the Fc-fusion protein products about which they have written. We believe that these accounts of the biologics development process in the context of a range of biological mechanisms and disease indications provide important lessons for the development of future therapeutic Fc-fusion proteins.

We thank all of the contributors to this book for taking the time to write what we hope you will find are useful discussions of these topics. We also thank Laura Shih, Wendy Lin, and Anne Chassin du Guerny and the editorial staff of Wiley-Blackwell for their editing support.

San Mateo, CA  
El Granada, CA  
Lexington, MA  
Santa Fe, NM

*Steven M. Chamow*  
*Henry Lowman*  
*Thomas Ryll*  
*Deborah Farson*

November 2013

## List of Contributors

**Judy R. Berlfein**

Biogen Idec  
Hemophilia Research  
14 Cambridge Center  
Cambridge, Massachusetts 02142  
USA

**Jody D. Berry**

BD Biosciences  
Antibody Discovery  
10770 North Torrey Pines Road  
La Jolla, California 92037  
USA

**Hervé Broly**

Merck Serono SA – Corsier sur Vevey  
Department of Biotech Process  
Sciences  
Zone Industrielle B  
1809 Fenil sur Corsier  
Switzerland

**Wenjin Cao**

Amgen, Inc.  
Drug Product Development  
1 Amgen Center Drive  
Thousand Oaks, California 91320  
USA

**Steven M. Chamow**

Chamow & Associates, Inc.  
San Mateo, California 94403  
USA

**Javier Chaparro-Riggers**

Rinat-Pfizer Inc.  
Protein Engineering Department  
230 E. Grand Avenue  
South San Francisco, California  
94080  
USA

**Alex Eon-Duval**

Merck Serono SA – Corsier sur Vevey  
Department of Biotech Process  
Sciences  
Zone Industrielle B  
1809 Fenil sur Corsier  
Switzerland

**Deborah A. Farson**

FarsonInk  
Santa Fe, New Mexico 87505  
USA

**Janean Fisher**

BD Biosciences  
Antibody Discovery  
10770 North Torrey Pines Road  
La Jolla, California 92037  
USA

**Ralf Gleixner**

F. Hoffmann-La Roche Ltd  
Grenzacherstr. 124  
4070 Basel  
Switzerland

**Uwe Gottschalk**

Sartorius-Stedim Biotech  
August-Spindler-Str. 11  
37079 Goettingen  
Germany

**Johanna Grossman**

San Francisco, California 94123  
USA

**Yao-Ming Huang**

Biogen Idec  
BioProcess Development  
5000 Davis Drive Research Triangle  
Park, NC 27709  
USA

**Esohe Idusogie**

OncoMed Pharmaceuticals  
800 Chesapeake Drive  
Redwood City, California 94063  
USA

**Rashmi Kshirsagar**

Biogen Idec  
BioProcess Development  
14 Cambridge Center  
Cambridge, Massachusetts 02142  
USA

**Angela L. Linderholm**

Davis, California 95616  
USA

**Ella Mendoza**

BD Biosciences  
Antibody Discovery  
10770 North Torrey Pines Road  
La Jolla, California 92037  
USA

**Massimo Morbidelli**

Institute for Chemical and  
Bioengineering  
Department of Chemistry and  
Applied Biosciences  
ETH Zurich  
Wolfgang-Pauli-Strasse 10  
8093 Zurich  
Switzerland

**Michael Mulkerrin**

OncoMed Pharmaceuticals  
800 Chesapeake Drive  
Redwood City, California 94063  
USA

**Benjamin Neunstoeklin**

Institute for Chemical and  
Bioengineering  
Department of Chemistry and  
Applied Biosciences  
ETH Zurich  
Wolfgang-Pauli-Strasse 10  
8093 Zurich  
Switzerland

**Robert J. Peach**

Receptos, Inc.  
10835 Road to the Cure, Suite #205  
San Diego, California 92121  
USA

**Robert T. Peters**

Biogen Idec  
Hemophilia Research  
14 Cambridge Center  
Cambridge, Massachusetts 02142  
USA

**Deirdre Murphy Piedmonte**

Amgen, Inc.  
Drug Product Development  
1 Amgen Center Drive  
Thousand Oaks, California 91320  
USA

**Jaume Pons**

Rinat-Pfizer Inc.  
Protein Engineering Department  
230 E. Grand Avenue  
South San Francisco, California  
94080  
USA

**Arvind Rajpal**

Rinat-Pfizer Inc.  
Protein Engineering Department  
230 E. Grand Avenue  
South San Francisco, California  
94080  
USA

**Margaret Speed Ricci**

Amgen, Inc.  
Drug Product Development  
1 Amgen Center Drive  
Thousand Oaks, California 91320  
USA

**Thomas Ryll**

Biogen Idec  
BioProcess Development  
14 Cambridge Center  
Cambridge, Massachusetts 02142  
USA

**Abhinav A. Shukla**

KBI Biopharma  
1101 Hamlin Road  
Durham, North Carolina 27704  
USA

**Miroslav Soos**

Institute for Chemical and  
Bioengineering  
Department of Chemistry and  
Applied Biosciences  
ETH Zurich  
Wolfgang-Pauli-Strasse 10  
8093 Zurich  
Switzerland

**Pavel Strop**

Rinat-Pfizer Inc.  
Protein Engineering Department  
230 E. Grand Avenue  
South San Francisco, California  
94080  
USA

**Dwayne Stupack**

University of California  
Department of Reproductive  
Medicine  
San Diego, California 92093  
USA

**Pascal Valax**

Merck Biodevelopment  
Site Montesquieu  
1 Rue Jacques Monod  
33650 Martillac  
France

**Barbara Woppmann**

Biogen Idec  
BioProcess Development  
14 Cambridge Center  
Cambridge, Massachusetts 02142  
USA

**Catherine Yang**

BD Biosciences  
Antibody Discovery  
10770 North Torrey Pines Road  
La Jolla, California 92037  
USA

**Ping Y. Yeh**

Amgen, Inc.  
Drug Product Development  
1 Amgen Center Drive  
Thousand Oaks, California 91320  
USA

***Yik Andy Yeung***

Rinat-Pfizer Inc.  
Protein Engineering Department  
230 E. Grand Avenue  
South San Francisco, California  
94080  
USA

***Shanique Young***

University of California  
Department of Reproductive  
Medicine  
San Diego, California 92093  
USA



# 1

## Introduction: Antibody Structure and Function

*Arvind Rajpal, Pavel Strop, Yik Andy Yeung, Javier Chaparro-Riggers, and Jaume Pons*

### 1.1

#### Introduction to Antibodies

Antibodies, a central part of humoral immunity, have increasingly become a dominant class of biotherapeutics in clinical development and are approved for use in patients. As with any successful endeavor, the history of monoclonal antibody therapeutics benefited from the pioneering work of many, such as Paul Ehrlich who in the late nineteenth century demonstrated that serum components had the ability to protect the host by “passive vaccination” [1], the seminal invention of monoclonal antibody generation using hybridoma technology by Kohler and Milstein [2], and the advent of recombinant technologies that sought to reduce the murine content in therapeutic antibodies [3].

During the process of generation of humoral immunity, the B-cell receptor (BCR) is formed by recombination between variable (V), diversity (D), and joining (J) exons, which define the antigen recognition element. This is combined with an immunoglobulin (Ig) constant domain element ( $\mu$  for IgM,  $\delta$  for IgD,  $\gamma$  for IgG (gamma immunoglobulin),  $\alpha$  for IgA, and  $\epsilon$  for IgE) that defines the isotype of the molecule. Sequences for these V, D, J, and constant domain genes for disparate organisms can be found through the International ImMunoGeneTics Information System<sup>®</sup> [4]. The different Ig subtypes are presented at different points during B-cell maturation. For instance, all naïve B cells express IgM and IgD, with IgM being the first secreted molecule. As the B cells mature and undergo class switching, a majority of them secrete either IgG or IgA, which are the most abundant class of Ig in plasma.

Characteristics like high neutralizing and recruitment of effector mechanisms, high affinity, and long resident half-life in plasma make the IgG isotype an ideal candidate for generation of therapeutic antibodies. Within the IgG isotype, there are four subtypes (IgG1–IgG4) with differing properties (Table 1.1). Most of the currently marketed IgGs are of the subtype IgG1 (Table 1.2).

**Table 1.1** Subtype properties.

Property	IgG1	IgG2	IgG3	IgG4
Heavy chain constant gene	$\gamma 1$	$\gamma 2$	$\gamma 3$	$\gamma 4$
Approximate molecular weight (kDa)	150	150	170	150
Mean serum level (mg/ml)	9	3	1	0.5
Half-life in serum (days)	21	21	7	21
ADCC	+	–	+	+/-
CDC	++	+	+++	–
Number of disulfides in hinge	2	4	11	2
Number of amino acids in hinge	15	12	62	12
Gm allotypes	4	1	13	–
Protein A binding	+++	+++	+	+++
Protein G binding	+++	+++	+++	+++

*Abbreviations:* ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity.

**Table 1.2** Marketed antibodies and antibody derivatives by target.

Trade name	International non-proprietary name	Target	Type	Indication
Benlysta <sup>®</sup>	Belimumab	BLyS	Human IgG1 $\lambda$	SLE
Soliris <sup>®</sup>	Eculizumab	C5	Humanized IgG2/4	PNH
Raptiva <sup>®</sup>	Efalizumab	CD11a	Humanized IgG1 $\kappa$	Psoriasis
Amevive <sup>®</sup>	Alefacept	CD2	CD2-binding domain of LFA3–IgG1 Fc fusion	Psoriasis
Rituxan <sup>®</sup>	Rituximab	CD20	Chimeric IgG1 $\kappa$	NHL, CLL, RA, GPA/MPA
Zevalin <sup>®</sup>	Ibritumomab tiuxetan	CD20	Murine IgG1 $\kappa$ –Y90/In111 conjugate	NHL
Bexxar <sup>®</sup>	Tositumomab-I131	CD20	Murine IgG2a $\lambda$ –I131 conjugate	NHL
Arzerra <sup>®</sup>	Ofatumumab	CD20	Human IgG1 $\kappa$	CLL
Orthoclone-OKT3 <sup>®</sup>	Muromonab-CD3	CD3	Murine IgG2a	Transplant rejection
Adcetris <sup>®</sup>	Brentuximab vedotin	CD30	Chimeric IgG1 $\kappa$ -conjugated MMAE	Hodgkin's lymphoma
Mylotarg <sup>®</sup>	Gemtuzumab ozogamicin	CD33	Humanized IgG4 $\kappa$ –calicheamicin conjugate	Leukemia
Campath-1H <sup>®</sup>	Alemtuzumab	CD52	Humanized IgG1 $\kappa$	Leukemia
Orencia <sup>®</sup>	Abatacept	CD80/CD86	CTLA4–IgG1 Fc fusion	RA
Nulojix <sup>®</sup>	Belatacept	CD80/CD86	CTLA4–IgG1 Fc fusion	Transplant rejection
Yervoy <sup>®</sup>	Ipilimumab	CTLA4	Human IgG1 $\kappa$	Metastatic melanoma

Erbix <sup>®</sup>	Cetuximab	EGFR	Chimeric IgG1κ	Colorectal cancer
Vectibix <sup>®</sup>	Panitumumab	EGFR	Human IgG2κ	Colorectal cancer
Removab <sup>®</sup>	Catumaxomab	EpCAM/ CD3	Rat IgG2b/mouse IgG2a	Malignant ascites
ReoPro <sup>®</sup>	Abciximab	gPIIb/ IIIa	Chimeric Fab	PCI complications
Herceptin <sup>®</sup>	Trastuzumab	Her2	Humanized IgG1κ	Breast cancer
Kadcyla <sup>®</sup>	Trastuzumab emtansine	Her2	Humanized IgG1κ–DM1 conjugate	Breast cancer
Perjeta <sup>®</sup>	Pertuzumab	Her2	Humanized IgG1κ	Breast cancer
Xolair <sup>®</sup>	Omalizumab	IgE	Humanized IgG1κ	Asthma
Ilaris <sup>®</sup>	Canakinumab	IL-1b	Human IgG1κ	CAPS, FCAS, MWS
Arcalyst <sup>®</sup>	Rilonacept	IL1	IL1R1–IL1RACp–IgG1 Fc fusion	CAPS
Stelara <sup>®</sup>	Ustekinumab	IL12/ IL23	Human IgG1κ	Psoriasis
Zenapax <sup>®</sup>	Daclizumab	IL2ra	Humanized IgG1	Transplant rejection
Simulect <sup>®</sup>	Basiliximab	IL2ra	Chimeric IgG1κ	Transplant rejection
Actemra <sup>®</sup>	Tocilizumab	IL6r	Humanized IgG1κ	RA
Tysabri <sup>®</sup>	Natalizumab	LFA4	Humanized IgG4κ	MS
Prolia <sup>®</sup>	Denosumab	RANKL	Human IgG2κ	Bone metastases
Synagis <sup>®</sup>	Pavilizumab	RSV F protein	Chimeric IgG1κ	RSV
Remicade <sup>®</sup>	Infliximab	TNFα	Chimeric IgGκ	RA
Enbrel <sup>®</sup>	Etanercept	TNFα	TNFrII–p75 ECD–IgG1 Fc fusion	RA
Humira <sup>®</sup>	Adalimumab	TNFα	Human IgG1κ	RA, Crohn's disease
Cimzia <sup>®</sup>	Certolizumab pegol	TNFα	Humanized IgG1κ Fab–PEG conjugate	RA
Simponi <sup>®</sup>	Golimumab	TNFα	Human IgG1κ	RA, PA, AS
Nplate <sup>®</sup>	Romiplostim	TPOr	Peptide–IgG1 Fc fusion	TCP, UC
Avastin <sup>®</sup>	Bevacizumab	VEGF	Humanized IgG1κ	Colorectal cancer
Lucentis <sup>®</sup>	Ranibizumab	VEGF	Humanized IgG1κ Fab	wAMD
Eylea <sup>®</sup>	Aflibercept	VEGF-A	VEGFr1 and VEGFr2–IgG1 Fc fusion	wAMD


*Abbreviations:* AS, ankylosing spondylitis; CAPS, cryopyrin-associated periodic syndrome; CLL, chronic lymphocytic leukemia; FCAS, familial cold autoinflammatory syndrome; GPA/MPA, granulomatosis with polyangiitis (Wegener's granulomatosis)/microscopic polyangiitis; MS, multiple sclerosis; MWS, Muckle–Wells syndrome; NHL, non-Hodgkin's lymphoma; PA, psoriatic arthritis; PCI, percutaneous coronary intervention; PNH, paroxysmal nocturnal hemoglobinuria; RA, rheumatoid arthritis; RSV, respiratory syncytial virus; SLE, systemic lupus erythematosus; TCP, thrombocytopenia; UC, ulcerative colitis; wAMD, neovascular (wet) age-related macular degeneration.

The ability of antibodies to recognize their antigens with exquisite specificity and high affinity makes them an attractive class of molecules to bind extracellular targets and generate a desired pharmacological effect. Antibodies also benefit from their ability to harness an active salvage pathway, mediated by the neonatal Fc receptor (FcRn), thereby enhancing their pharmacokinetic (PK) life span and mitigating the need for frequent dosing. The antibodies and antibody derivatives approved in the United States and the European Union (Table 1.2) span a wide range of therapeutic areas, including oncology, autoimmunity, ophthalmology, and transplant rejection. They also harness disparate modes of action like blockade of ligand binding and subsequent signaling, and receptor and signal activation, which target effector functions (antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)), and delivery of cytotoxic payload.

Antibodies are generated by the assembly of two heavy chains and two light chains to produce two antigen-binding sites and a single constant domain region (Figure 1.1, panel a). The constant domain sequence in the heavy chain designates the subtype (Table 1.1). The light chains can belong to two families ( $\lambda$  and  $\kappa$ ), with most of the currently marketed antibodies belonging to the  $\kappa$  family.

The antigen-binding regions can be derived by proteolytic cleavage of the antibody to generate antigen-binding fragments (Fab) and the constant fragment (Fc, also known as the fragment of crystallization). The Fab comprises the variable regions (variable heavy (VH) [11] and variable light (VL)) and constant regions ( $C_{H1}$  and  $C_{\kappa}/C_{\lambda}$ ). Within these variable regions reside loops called complementarity determining regions (CDRs) responsible for direct interaction with the antigen (Figure 1.1, panel b). Because of the significant variability in the number of amino acids in these CDRs, there are multiple numbering schemes for the variable domains [12,13] but only one widely used numbering scheme for the constant domain (including portions of the  $C_{H1}$ , hinge, and the Fc) called the EU numbering system [14].

There are two general methods to generate antibodies in the laboratory. The first utilizes the traditional methodology employing immunization followed by recovery of functional clones either by hybridoma technology or, more recently, by recombinant cloning of variable domains from previously isolated B cells displaying and expressing the desired antigen-binding characteristics. There are several variations of these approaches. The first approach includes the immunization of transgenic animals expressing subsets of the human Ig repertoire (see review by Lonberg [15]) and isolation of rare B-cell clones from humans exposed to specific antigens of interest [16]. The second approach requires selecting from a large *in vitro* displayed repertoire either amplified from natural sources (i.e., human peripheral blood lymphocytes in Ref. [17]) or designed synthetically to reflect natural and/or desired properties in the binding sites of antibodies [18,19]. This approach requires the use of a genotype–phenotype linkage strategy, such as phage or yeast display, which allows for the recovery of genes for antibodies displaying appropriate binding characteristics for the antigen.



**Figure 1.1** Structure and features of the IgG and its interactions. (a) The structure of a full-length IgG is shown in ribbon representation with transparent molecular surface. One heavy chain is shown in blue and one light chain in magenta. The other heavy chain and light chain are shown in gray for clarity. In this orientation, two Fab domains sit on top of the Fc domain and are connected in the middle by the hinge region. The Fab domain is composed of the heavy chain  $V_H$  and  $C_H1$  domains and the light chain  $V_L$  and  $C_L$  domains—Protein Data Bank (PDB) [5] code 1HZH [6]. (b) Each variable domain contains three variable loops (L1–L3 on light chain and H1–H3 on heavy chain) that make up the antigen-binding site—PDB code 1HZH [6]. (c) The Fc region is composed of the dimer of  $C_H2$  and  $C_H3$  domains. The  $C_H3$  domains form a tight interaction while the  $C_H2$  domains interact through protein–protein, protein–carbohydrate,

and carbohydrate–carbohydrate contacts—PDB code 1HZH [6]. (d) The hinge region is composed of a flexible region covalently tied together through disulfide bridges. Structures of the  $Fc\gamma R11a$  and  $Fc\gamma R11a$  bound to the Fc are shown. The structures reveal that both receptors bind to the  $C_H2$  domain near the hinge and carbohydrates and upon their binding create an asymmetry such that the second  $Fc\gamma R$  is unable to bind. In this panel,  $Fc\gamma R11a$  is shown in green, and the  $Fc\gamma R11b$  is shown in purple—PDB codes 3RY6 [7] and 1T83 [8]. (e) The crystal structure of the complex between the Fc and FcRn reveals that FcRn binds between the  $C_H2$  and  $C_H3$  domains in the Fc. FcRn chains are shown in red and orange—PDB code 1FRT [9]. (f) Interestingly, the same region also binds to bacterial Protein A commonly used for purification—PDB code 1FC2 [10].

## 1.2

### General Domain and Structure of IgG

Topologically, the IgG is composed of two heavy chains (50 kDa each) and two light chains (25 kDa each) with total molecular weight of approximately 150 kDa. Each heavy chain is composed of four domains: the variable domain (VH), C<sub>H</sub>1, C<sub>H</sub>2, and C<sub>H</sub>3. The light chain is composed of variable domain (VL) and constant domain (CL). All domains in the IgG are members of the Ig-like domain family and share a common Greek-key beta-sandwich structure with conserved intradomain disulfide bonds. The CLs contain seven strands with three in one sheet, and four in the other, while the VLs contain two more strands, resulting in two sheets of four and five strands.

The light chain pairs up with the heavy chain VH and C<sub>H</sub>1 domains to form the Fab fragment, while the heavy chain C<sub>H</sub>2 and C<sub>H</sub>3 domains dimerize with additional heavy chain C<sub>H</sub>2 and C<sub>H</sub>3 domains to form the Fc region (Figure 1.1, panel c). The Fc domain is connected to the Fab domain via a flexible hinge region that contains several disulfide bridges that covalently link the two heavy chains together. The light chain and heavy chains are also connected by one disulfide bridge, but the connectivity differs among the IgG subclasses (Figure 1.2). The overall structure of IgG resembles a Y-shape, with the Fc region forming the base while the two Fab domains are available for binding to the antigen [6]. Studies have shown that in solution the Fab domains can adopt a variety of conformations with regard to the Fc region.

#### 1.2.1


#### Structural Aspects Important for Fc Fusion(s)

##### 1.2.1.1 Fc Protein–Protein Interactions

While the Fab region of an antibody is responsible for binding and specificity to a given target, the Fc region has many important functions outside its role as a structural scaffold. The Fc region is responsible for the long half-life of antibodies as well as for their effector functions including ADCC, CDC, and phagocytosis [20].

The long half-life of human IgGs relative to other serum proteins is a consequence of the pH-dependent interaction with the FcRn [21–23]. In the endosome, FcRn binds to the Fc region and recycles the antibody back to the plasma membrane, where the increase in pH releases the antibody back to the serum, thus rescuing it from degradation. The details of FcRn binding and its effects on antibody pharmacokinetics, including results from modulating FcRn interaction by protein engineering, are discussed in Section 1.3.3. One FcRn binds between the C<sub>H</sub>2 and C<sub>H</sub>3 domains of an Fc dimer half (Figure 1.1, panel e) [21]; therefore, up to two FcRns can bind to a single Fc.

Fc region is also responsible for binding to bacterial Protein A [10] and Protein G [24], which are commonly used for purification of Fc-containing proteins. Although Protein A binds to Fc mainly through hydrophobic interactions and



**Figure 1.2** Interchain disulfide topology in human IgG subclasses. Only H-H hinge and H-L chain disulfides are shown. (a) IgG1, (b) IgG2, (c) IgG3, and (d) IgG4.

Protein G through charged and polar interactions, Proteins A and G bind to a similar site on Fc domain and compete with each other (Figure 1.1, panel f). Interestingly, the binding occurs between the  $C_{H2}$  and  $C_{H3}$  domains of the Fc and largely overlaps with the FcRn binding site.

ADCC function is mediated by the interaction of the Fc region with Fc $\gamma$  receptors (Fc $\gamma$ Rs). Biochemical data and structures of Fc in complex with Fc $\gamma$ RIII and Fc $\gamma$ RII reveal that the Fc $\gamma$ Rs bind to the combination of the Fc  $C_{H2}$  domain and the lower hinge region (Figure 1.1, panel d) [7,8,25]. Members of the Fc $\gamma$  family have been found to bind to the same region of Fc [20,26,27] and form a 1:1 asymmetric complex where one Fc $\gamma$ R interacts with the dimer of Fc. The binding of one Fc $\gamma$ RIII to Fc induces asymmetry in the Fc region and prevents a second interaction. While the detailed structural understanding is not available for the Fc-C1q interaction, biochemical data suggest that C1q binds mainly to the  $C_{H2}$  domain with an overlapping, but nonidentical, binding site of Fc $\gamma$ RIII [28]. The

details of the interaction between the Fc and Fc $\gamma$  receptors, as well as the engineering of effector function, are further discussed in Section 1.4.2.1.

### 1.2.1.2 Fc Glycosylation

The Fc region of IgG has a conserved glycosylation site in the C<sub>H</sub>2 domain at position N297 (Figure 1.1, panel c). Glycosylation of the C<sub>H</sub>2 domain is important in achieving optimal effector function [29] and complement activation; it also contributes to overall IgG stability [30]. Antibodies purified from human serum have been found to contain heterogeneous oligosaccharides where each C<sub>H</sub>2 domain can contain one of many potential glycans [31]. Therapeutic Fc-containing proteins that are expressed in Chinese hamster ovary (CHO) or human embryo kidney 293 (HEK293) cells typically contain a mixture of glycoforms, with G0F being the most abundant, followed by G1F and G2F [32,33]. The attachment of the glycans at position Asn297 in the C<sub>H</sub>2 domain positions the carbohydrates to interact with each other and to form a part of the Fc dimer interface. Because of carbohydrate sequestration into the space between the two C<sub>H</sub>2 domains and significant carbohydrate–carbohydrate and carbohydrate–protein contacts, the carbohydrates in the Fc crystal structures are relatively well ordered.

The glycosylation of the Fc has been found to influence biological activity as well as stability of IgGs [34,35]. The removal of the core fucose enhances ADCC activation of Fc $\gamma$ R1IIa on natural killer (NK) cells but does not change the binding of Fc $\gamma$ RI or C1q [36]. Increased ADCC has also been observed with the presence of bisecting *N*-acetylglucosamine in the context of fucosylated IgG, although the effect appears to be smaller than removal of the core fucose [37]. Sialylated IgGs have been suggested to enhance anti-inflammatory properties [38]; however, more work is needed to understand this effect and potential mechanism.

### 1.2.1.3 Hinge and Interchain Disulfide Bonds

The hinge region of human IgGs (IgG1, IgG2, and IgG4) differs between the subtypes both in the hinge length (12–15 residues) and in number of disulfides linking the two heavy chains together (2–4 residues) (Figure 1.2). In addition, the position of the light chain–heavy chain linkage differs among the human IgG subtypes (Figure 1.2). In human IgG1, two disulfides link the heavy chains together while human IgG2 contains four disulfides and a shorter hinge. The presence of an increased number of disulfides as well as a shorter hinge likely decreases the flexibility of hIgG2 Fab regions relative to hIgG1. The hinge can have a profound impact on antibody properties. For example, the sequence in the hinge near the disulfides has been found to be important in the ability of IgG4s to exchange half molecules *in vivo* and under certain conditions *in vitro* [39,40]. The absence of one of the proline residues in the hinge of IgG4 coupled with substitution in the C<sub>H</sub>3 domain allows IgG4 to form half-antibodies and form bispecific antibodies by exchanging with other IgG4s (Figure 1.2).



## 1.3

## The Neonatal Fc Receptor

## 1.3.1

## FcRn Function and Expression

One major characteristic of IgG, which differs from other Ig isotypes and most of the other serum proteins, is its long serum half-life. Typically, serum proteins and other Ig isotypes have half-lives of <1 week, for example, fibrinogen (1–3 days), IgD (2–5 days), IgM (4–6 days), IgA (3–7 days), and haptoglobin (~5 days) [41–44]; however, serum IgGs have half-lives of ~3 weeks (Table 1.3). The prolonged half-lives of IgGs are mainly due to the protective and recycling action of the FcRn [22,45,46].

**Table 1.3** Summary of the pharmacokinetics of antibody variants engineered for increased FcRn binding in nonhuman primates.

Mutation(s) (EU numbering)	IgG isotype	Target antigen	FcRn affinity increase at pH 6.0 (fold)	Serum half- life (fold of WT)	Clearance (Fold of WT)	Source
M428L	IgG2	$\alpha$ -HBV OST577	~7 $\times$ (human) <sup>a)</sup> ~8 $\times$ (rhesus) <sup>a)</sup>	1.8 $\times$ (rhesus)	0.56 $\times$ (rhesus)	[47]
T250Q/ M428L	IgG2	$\alpha$ -HBV OST577	~28 $\times$ (human) <sup>a)</sup> ~27 $\times$ (rhesus) <sup>a)</sup>	1.8 $\times$ (rhesus)	0.36 $\times$ (rhesus)	[47]
M252Y/ S254T/ T256E	IgG1	$\alpha$ -RSV	~11 $\times$ (human) <sup>b)</sup>	3.5 $\times$ (cyno)	N.A.	[48]
T250Q/ M428L	IgG1	$\alpha$ -HBV OST577	~9 $\times$ (rhesus) <sup>b)</sup> ~29 $\times$ (human) <sup>a)</sup> ~37 $\times$ (rhesus) <sup>a)</sup>	2.5 $\times$ (rhesus)	0.42 $\times$ (rhesus)	[49]
P257I/ N434H	IgG1	TNF $\alpha$	~16 $\times$ (human) <sup>c)</sup> ~52 $\times$ (cyno) <sup>c)</sup>	0.8 $\times$ <sup>d)</sup> (cyno)	1.1 $\times$ <sup>d)</sup> (cyno)	[50]
D376V/ N434H	IgG1	TNF $\alpha$	~15 $\times$ (human) <sup>c)</sup> ~52 $\times$ (cyno) <sup>c)</sup>	0.7 $\times$ (cyno)	1.3 $\times$ <sup>d)</sup> (cyno)	[50]
T250Q/ M428L	IgG1	TNF $\alpha$	~40 $\times$ (cyno) <sup>c)</sup>	0.9 $\times$ (cyno)	1.1 $\times$ <sup>d)</sup> (cyno)	[51]
P257I/ Q311I	IgG1	TNF $\alpha$	~19 $\times$ (human) <sup>c)</sup> ~80 $\times$ (cyno) <sup>c)</sup>	0.8 $\times$ (cyno)	0.8 $\times$ <sup>d)</sup> (cyno)	[50,51]
N434A	IgG1	Unknown	~3 $\times$ (human) <sup>b)</sup>	1.6 $\times$ (cyno)	0.54 $\times$ (cyno)	[52]
N434W	IgG1	Unknown	~38 $\times$ (human) <sup>b)</sup>	1.0 $\times$ <sup>d)</sup> (cyno)	1.2 $\times$ <sup>d)</sup> (cyno)	[52]

(continued)

Table 1.3 (Continued)

Mutation(s) (EU numbering)	IgG isotype	Target antigen	FcRn affinity increase at pH 6.0 (fold)	Serum half- life (fold of WT)	Clearance (Fold of WT)	Source
M428L/ N434S	IgG1	$\alpha$ -VEGF	$\sim 11\times$ (human) <sup>b)</sup>	$3.2\times$ (cyno)	$0.32\times$ (cyno)	[53]
V259I/ V308F	IgG1	$\alpha$ -VEGF	$\sim 6\times$ (human) <sup>b)</sup>	$1.7\times$ (cyno)	$0.63\times$ (cyno)	[53]
M252Y/ S254T/ T256E	IgG1	$\alpha$ -VEGF	$\sim 7\times$ (human) <sup>b)</sup>	$2.5\times$ (cyno)	$0.42\times$ (cyno)	[53]
V259I/ V308F/ M428L	IgG1	$\alpha$ -VEGF	$\sim 20\times$ (human) <sup>b)</sup>	$2.6\times$ (cyno)	$0.39\times$ (cyno)	[53]
M428L/ N434S	IgG1	$\alpha$ -EGFR	$\sim 11\times$ (human) <sup>b)</sup>	$3.1\times$ (cyno)	$0.31\times$ (cyno)	[53]
N434H	IgG1	$\alpha$ -VEGF	$\sim 4\times$ (human) <sup>b)</sup>	$1.6\times$ (cyno)	$0.62\times$ (cyno)	[54]
T307Q/ N434A	IgG1	$\alpha$ -VEGF	$\sim 5\times$ (cyno) <sup>b)</sup> $\sim 18\times$ (human) <sup>b)</sup>	$2.2\times$ (cyno)	$0.52\times$ (cyno)	[54]
T307Q/ N434S	IgG1	$\alpha$ -VEGF	$\sim 10\times$ (cyno) <sup>b)</sup> $\sim 10\times$ (human) <sup>b)</sup>	$2.0\times$ (cyno)	$0.49\times$ (cyno)	[54]
T307Q/ E380A/ N434A	IgG1	$\alpha$ -VEGF	$\sim 12\times$ (cyno) <sup>b)</sup> $\sim 13\times$ (human) <sup>b)</sup>	$1.9\times$ (cyno)	$0.57\times$ (cyno)	[54]
V308P/ N434A	IgG1	$\alpha$ -VEGF	$\sim 15\times$ (cyno) <sup>b)</sup> $\sim 26\times$ (human) <sup>b)</sup>	$1.8\times$ (cyno)	$0.57\times$ (cyno)	[54]
N434H	IgG1 (N297A)	CD4	$\sim 34\times$ (cyno) <sup>b)</sup> $\sim 3\times$ (human) <sup>b)</sup>	N/A	$0.50\times$ (baboon)	[55]
V308P	IgG4	5 unknown targets	$\sim 3\times$ (baboon) <sup>b)</sup> $\sim 40\text{--}390\times$ (cyno) <sup>c)</sup>	$2.0\text{--}3.3\times$ (cyno)	$0.22\text{--}0.74\times$ (cyno)	[56]
T250Q/ M428L	IgG4	5 unknown targets	$\sim 11\text{--}110\times$ (cyno) <sup>c)</sup>	$0.9\text{--}2.6\times$ (cyno)	$0.31\text{--}0.89\times$ (cyno)	[56]

Abbreviations: EGFR, endothelial cell growth factor receptor; FcRn, neonatal Fc receptor; HBV, hepatitis B virus; N/A: not available; RSV, respiratory syncytial virus; TNF, tumor necrosis factor; VEGF, vascular endothelial cell growth factor.

a) IC<sub>50</sub> binding ratio performed on FcRn-transfected cells.

b) Monovalent interaction: injecting FcRn over surface-conjugated antibodies.

c) Bivalent interaction: injecting antibodies over surface-conjugated FcRn.

d) No statistically significant difference.